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Background: Levodopa/carbidopa intestinal gel therapy (LCIG) can efﬁciently improve several motor and
non-motor symptoms of advanced Parkinson's disease (PD). The recently developed Movement Disorder
Society-sponsored Uniﬁed Parkinson's Disease Rating Scale (MDS-UPDRS) improved the original UPDRS
making it a more robust tool to evaluate therapeutic changes. However, previous studies have not used
the MDS-UPDRS and the Uniﬁed Dyskinesia Rating Scale (UDysRS) to assess the efﬁcacy of LCIG.
Objectives: Our aim was to determine if the MDS-UPDRS and UDysRS could detect improvement in the
experiences of daily living following 1-year LCIG treatment.
Methods: In this prospective, multicenter, open-label study, 34 consecutive patients undergoing LCIG
treatment were enrolled. Patients were examined twice: prior to LCIG initiation and 12 months later.
Impact of PD-related symptoms and dyskinesia was assessed by the MDS-UPDRS and UDysRS.
Results: Non-motor Experiences of Daily Living part of MDS-UPDRS improved from 20 (median,
interquartile-range, IQR:14e23) to 16 points (median, IQR:12e20, p ¼ 0.044) and the Motor Experiences
of Daily Living ameliorated from 24 (median, IQR:20e29) to 18 points (median, IQR:13e25, p ¼ 0.025).
Health-related quality of life, measured by PDQ-39, also improved from 35.4 (median, IQR:26.9e50.3) to
27.0 (median, IQR:21.3e31.4) points (p ¼ 0.003). The total score of UDysRS decreased from 47 (median,
IQR:36e54) to 34 (median, IQR:21e45) points (p ¼ 0.003).
Conclusions: As far as the authors are aware of, our paper is the ﬁrst to evaluate the impact of LCIG on
dyskinesia by the means of UDysRS. Changes in MDS-UPDRS and UDysRS conﬁrm that LCIG treatment
can efﬁciently improve experiences of daily living in advanced PD.
© 2017 Elsevier Ltd. All rights reserved.dysregulation syndrome; ESS, Epworth Sleepiness Scale; HRQoL, Health-related Quality of Life; HYS, Hoehn-Yahr Stage;
e; LCIG, levodopa/carbidopa intestinal gel; LED, levodopa-equivalent dosage; MADRS, Montgomery-Asberg Depression
DS-UPDRS); MDS-UPDRS, The Movement Disorder Society-sponsored Uniﬁed Parkinson's Disease Rating Scale; ME,
otor Experiences of Daily Living (Part II of MDS-UPDRS); MoCA, Montreal Cognitive Assessment; nM-EDL, Non-motor
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Although in the early stages of Parkinson's disease (PD) most
motor and non-motor symptoms can be well controlled by dopa-
minergic therapy (honey-moon phase), motor complications
eventually develop in conjunction with disease progression.
Despite optimal pharmacological treatment, the control of motor
and non-motor ﬂuctuations is often challenging. In this advanced
stage of PD, only functional neuromodulation and pump therapies
can provide dramatic and long-lasting improvement in both PD-
related symptoms and the health-related quality of life (HRQoL).
Levodopa/carbidopa intestinal gel (LCIG) therapy provides
continuous enteral infusion of water-soluble formulation of levo-
dopa into the site of absorption via percutaneous endoscopic gas-
trostomy tube with jejunal extension (PEG-J). Since the approval of
LCIG treatment in the European Union in 2004, extensive amounts
of information regarding its efﬁcacy and safety have been collected.
However, so far there is only a recent controlled study [1], and the
long-term information is still sparse and incomplete [2e4].
Although all available long-term studies clearly demonstrated
dramatic improvement in HRQoL, they provided conﬂicting data on
the efﬁcacy of LCIG on the experiences of daily living. Whereas
some studies demonstrated that the motor aspects of daily living
(Uniﬁed Parkinson's Disease Rating Scale Part 2 score, UPDRS-2)
improved compared to baseline [4e7], others did not reveal any
changes [8,9] at all, or did not analyze and report this information
separately [2,10,11]. Meanwhile, some studies demonstrated
worsening in UPDRS-2 compared to baseline [12]. We can partly
explain these incongruent ﬁndings by some methodological issues.
All of the previously mentioned studies utilized the UPDRS and
consequently the UPDRS-2 to assess changes in the motor experi-
ences of daily living. Recently theMovement Disorders Society Task
Force identiﬁed several weaknesses of UPDRS on its ability to
capture PD-related symptoms and their consequences; and sub-
sequently published a revised and more reliable version called
Movement Disorders Society-sponsored Uniﬁed Parkinson's Dis-
ease Rating Scale (MDS-UPDRS) [13]. The MDS-UPDRS [13] is a
clinimetrically validated scale to assess non-motor aspects of ex-
periences of daily living (Part I, nM-EDL), motor aspects of experi-
ences of daily living (Part II, M-EDL), motor examination (part III,
ME) and motor complications (Part IV, MC). Although the MDS-
UPDRS was published in 2008, none of the larger studies has uti-
lized it to assess the efﬁcacy of LCIG so far.
Additionally, all major LCIG studies demonstrated a dramatic
improvement in ﬂuctuations and dyskinesia by the increase in ON
time without dyskinesia and the decrease in OFF time [7,8,11,14,15].
However, they assessed only patient diaries and the motor
complication part of UPDRS (UPDRS-4) to detect these changes.
Because these instruments are only capable of detecting the tem-
poral characteristics of dyskinesia, they cannot provide information
concerning the disability and the direct impact of dyskinesia on
daily living. Recently the Uniﬁed Dyskinesia Rating Scale (UDysRS)
was developed to reliably measure all aspects of dyskinesia [16].
UDysRS has four parts evaluating the presence and impact of ON-
and OFF-dyskinesia on patients' experiences of daily living
(UDysRS-1 and UDysRS-2, respectively), and the intensity and
disability of dyskinesia (UDysRS-3 and UDysRS-4, respectively).
Therefore, the UDysRS is suitable for simultaneously detecting the
severity of dyskinesia (‘Objective’ parts, UDysRS-3 and UDysRS-4)
and their inﬂuence on daily living (‘Historical’ parts, UDysRS-1
and UDysRS-2). Moreover, a recent study demonstrated that
UDysRS has better sensitivity to detect changes in dyskinesia andPlease cite this article in press as: A. Juhasz, et al., Levodopa/carbidopa i
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[17]. Despite its advantages over UPDRS-4, none of the LCIG-related
studies applied the UDysRS for detecting changes in dyskinesia.
The Hungarian DUODOPA Registry (LCIG01), established origi-
nally by the University of Pecs independently from the industry,
now includes all the Hungarian Movement Disorder Centers per-
forming LCIG treatment (Departments of Neurology at the Uni-
versity of Pecs, Pecs; the Semmelweis University, Budapest; the
University of Szeged, Szeged, and the Borsod-Abaúj-Zemplen
County Hospital, Miskolc). The aim of this multicenter registry is to
evaluate the efﬁcacy and safety proﬁle of LCIG treatment in
Hungary simultaneously serving both clinical and research pur-
poses. This registry was approved by the National Ethics Board and
the National Institute of Pharmacy (OGYI/47439-6/2013).
Based on the Hungarian DUODOPA Registry, we intended to
evaluate how the LCIG can improve dyskinesia and the experiences
of daily living in advanced PD following 1-year treatment by the
means of MDS-UPDRS and UDysRS.
2. Materials and methods
2.1. Patients
In this prospective, open-label and multicenter study, 34
consecutive patients receiving LCIG treatment and participating in
the Hungarian DUODOPA Registry were enrolled. All patients ful-
ﬁlled the UK Brain Bank criteria for PD. Each subject gave written
informed consent in accordance with the ethics approval.
Following the Hungarian guidelines for advanced PD, the indication
for the LCIG treatment was the severe motor ﬂuctuations despite of
optimal oral antiparkinsonian therapy in all cases [18]. Since in
Hungary only deep brain stimulation and LCIG are available, we
could offer only these two options. The selection of the recom-
mended advanced therapy was based on the results of the preop-
erative evaluation, the patients' preference and the ﬁnancial
availability. The option of deep brain stimulation was either
medically contraindicated (n ¼ 30) or refused by the patients
(n ¼ 4).
2.2. Rating scales utilized in the study
Patients were examined twice: prior to the LCIG treatment
initiation (baseline) and 12 months later (follow-up). Severity of PD
symptoms was globally assessed by the Hungarian validated
version of the MDS-UPDRS [19]. Included in the MC part, MDS-
UPDRS has two items evaluating the time spent with dyskinesia
(excluding OFF-state dystonia, item 4.1) and time spent in OFF state
(item 4.3). Each item can have a value between 0 (none) to 4 (>75%
of awaking day). As a part of theMDS-UPDRS, the Hoehn-Yahr Scale
was also taken to detect the overall severity of PD.
To assess the severity and impact of dyskinesia, the Hungarian
validated version [20] of Uniﬁed Dyskinesia Rating Scale (UDysRS)
[16] was also taken. Besides, patient diaries were also obtained to
calculate the average ON time without dyskinesia, ON time with
slight dyskinesia, ON time with severe dyskinesia, OFF time and
time spent with daytime sleep based on three consecutive days.
Subsequently, ‘good time’ was also determined as the sum of ON
time without dyskinesia and ON time with slight dyskinesia as
described elsewhere [21].
We also applied the Patient's Global Impressione Severity scale
(PGI-S) to evaluate the overall illness severity on a 7-item Likert-
type scale: 1: normal, not at all ill; 2: borderline ill; 3: mildly ill;ntestinal gel can improve both motor and non-motor experiences of
onism and Related Disorders (2017), http://dx.doi.org/10.1016/
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Subsequently, the portion of patients reporting severe disease state
(i.e., a PGI-S score > 4) was calculated.
To assess non-motor symptoms globally, the Non-Motor
Symptoms Scale (NMSS) was also included. This scale is obtained
by trained professionals and capable of simultaneously capturing
the severity and frequency of nine non-motor domains typical for
PD (sleep, cardiovascular, cognitive, mood, hallucinatory, gastro-
intestinal, urinary and sexual symptoms, and miscellaneous
problems).
Presence and severity of sleep disturbances were speciﬁcally
measured by the Parkinson's Disease Sleep Scale 2nd version
(PDSS-2). The threshold indicating clinically relevant sleep prob-
lems is 11 points for the Hungarian validated version of PDSS-2
[22]. Meantime, daytime sleepiness was assessed by the Epworth
Sleepiness Scale with the cutoff value of 8 points [22].
As part of the neuropsychological domain, depression (Hun-
garian validated version of Montgomery Depression Scale) and
cognitive performance (Hungarian validated versions of Montreal
Cognitive Assessment, MoCA [23] and Mini-Mental Status Exami-
nation, MMSE [24]) were also examined. HRQoL was measured
simultaneously by the Hungarian validated version of PDQ-39 and
EQ-5D [21]. Patients were evaluated in ON state while receiving
their usual antiparkinsonian and other medications.
Treatment responsiveness was also ascertained by the threshold
of minimal clinically important difference (MCID) threshold values.
MCID is the smallest change of scores that are clinically meaningful
to patients and clinicians. Therefore, any therapeutic changes not
exceeding the MCID threshold value may be judged as clinically
irrelevant. Based on the established values, improvements higher
than 2 points on MADRS [25], 3.44 points on PDSS-2 [26] or 3.25
points on the MDS-UPDRS ME part [27] were considered clinically
meaningful.
2.3. Statistical analysis
For statistical analyses the IBM SPSS software package (version
23.0.1, IBM Inc., Armonk, NY, USA) was utilized. Since data from the
obtained scales were ordinal and did not follow the normal dis-
tribution, non-parametric tests were performed. We calculated
medianswith interquartile range (IQR: 25th-75th percentile) for the
description of the data. Wilcoxon signed rank test was applied for
the comparison of baseline and follow-up values. For dichotomous
variables, (e.g., presence or absence of sleep-problems, usage of
levodopa, etc.) a McNemar test, and for categorical variables Chi-
square tests were used. Following the recommendations of Roth-
man [28], in our open-label study we did not perform post-hoc
corrections. To allow better interpretation of the data, we calcu-
lated effect-sizes using the following formula suitable for
nonparametric groups:
Effect size ¼ Zﬃﬃﬃﬃ
N
p
where Z is the Z statistic produced by the Wilcoxon tests and N is
the size of the study. These effect-size values can be compared to
proposed thresholds of 0.1, 0.3 and 0.5 for small, medium and large
magnitudes of change, respectively [29]. Statistical signiﬁcance
level was set at 5%.
3. Results
3.1. Demographic and PD-related clinical data
The study population consisted of 34 PD patients (19 males,Please cite this article in press as: A. Juhasz, et al., Levodopa/carbidopa i
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patients had rigid-akinetic and 15 had mixed-type of PD. The
disease-speciﬁc characteristics of the enrolled patients and their
baseline medication are summarized in Table 1.
At follow-up, the average levodopa dosage was
1222.4 ± 667.0 mg. Out of the 34 patients, 3 received 24-h LCIG
treatment, while the rest was on 16-h daytime treatment only.
Whereas 27 patients were on LCIG monotherapy, 3 patients
received water-soluble levodopa formulation in the morning in
order to be capable of assembling and initiating the Duodopa®
system. The indication for low dosage dopamine-agonist treatment
(4e6 mg ropinirole in 2 cases, 1.05 mg pramipexole in 1 case and
4 mg rotigotine in 1 case) was the better control of non-motor
symptoms, especially mood- and sleep-related problems. Besides,
5 patients received typically 100e200 mg levodopa/carbidopa/
entacapone tablets at bedtime for optimal nighttime control.
3.2. Severity of PD
With the prominent exception of the ME, most parts of the
MDS-UPDRS (nM-EDL, M-EDL and MC) demonstrated signiﬁcant
improvement representing large effect-sizes (0.51e0.77). Changes
in the ME part were neither clinically meaningful in magnitude nor
statistically signiﬁcant (Table 2). Although the HYS showed some
improvement, it did not reach the level of statistical signiﬁcance
(p ¼ 0.095). Based on PGI-S, signiﬁcantly less patients reported
severe disease state (a PGI-S score > 4) at follow-up compared to
the baseline (11 vs. 20, p ¼ 0.049, McNemar test).
Although the severity of dyskinesia demonstrated only
tendentious changes (UDysRS Part 3, from 10 to 8 points, medians,
p ¼ 0.063), it had a medium effect-size (0.47). The disability asso-
ciated with dyskinesia (Part 4) and the impact of both ON and OFF
dyskinesia on daily living (Parts 1&2, respectively) improved
signiﬁcantly to a large extent (effect-size: 0.67e0.69, Table 2). The
analysis of the patient diaries revealed that the median OFF time
signiﬁcantly decreased from 5.0 (IQR: 4.0e9.0) to 0.5 h (IQR:
0.0e1.8, p ¼ 0.001) while the ‘good time’ (the sum of ON without
dyskinesia and ON with slight, non-disturbing dyskinesia)
increased from 8.0 (IQR: 6.0e10.5) to 14.8 h (IQR: 13.0e15.5,
p ¼ 0.001, effect-size ¼ 0.87, Table 2).
3.3. HRQoL
HRQoL also improved from 35.4 (IQR: 26.9e50.3) to 27.0 (IQR:
21.3e31.4) points (p ¼ 0.003, effect-size ¼ 0.75) measured by the
PDQ-39 Summary Index. Meanwhile, the EQ-5D index value
increased from 0.518 (IQR: 0.393e0.604) to 0.629 (IQR:
0.543e0.691, p ¼ 0.043, effect-size ¼ 0.52), also advocating a better
HRQoL status.
3.4. Non-motor symptoms
Although only the cardiovascular and mood sections showed
signiﬁcant changes at follow-up (effect-sizes: 0.56e0.60), the total
score of NMSS also signiﬁcantly improved (p ¼ 0.027, effect-size:
0.56, Table 2). At baseline, 15 patients reported sleep problems
(i.e., a total score of PDSS-2 11 points), but 1 year after the LCIG
initiation only 7 did (p¼ 0.021, McNemar test). Simultaneously, the
total score of PDSS-2 decreased from 25 (IQR: 19e34) to 20 (IQR:
14e29) points (P ¼ 0.042, effect-size ¼ 0.34). Since the magnitude
of this improvement exceeded the MCID threshold, the observed
change in sleep quality was clinically meaningful.
Before LCIG, 19 patients reported daytime sleepiness (i.e., total
score of ESS8 points), which decreased to 12 patients at follow-up
(p ¼ 0.289, McNemar test). Meanwhile, neither the ESS nor thentestinal gel can improve both motor and non-motor experiences of
onism and Related Disorders (2017), http://dx.doi.org/10.1016/
Table 1
Descriptive data of the study population at baseline.
Mean or count SD or percentage Median Percentile 25 Percentile 75
Age (years) 67 6 69 63 72
Disease duration (years) 12 5 12 9 15
Levodopa treatment (years) 10 6 9 6 12
Duration of ﬂuctuations (years) 4 3 4 2 6
Education (years) 14 3 15 11 16
Sex Male 19 55.9%
Female 15 44.1%
Disease subtype Rigid-akinetic 19 55.9%
Mixed 15 44.1%
Handedness Right 31 91.2%
Left 3 8.8%
Hoehn-Yahr Scale 2 9 26.5%
3 18 52.9%
4 6 17.6%
5 1 2.9%
Levodopa usage 34 100.0%
Dopamine agonist usage 21 61.8%
Monoamine-oxidase inhibitor usage 7 20.6%
Catechol-O-methyl transferase inhibitor
usage
26 76.5%
Anticholinergic drugs usage 0 0.0%
Levodopa LED (mg) 1000.2 577.6 940.0 700.0 1155.0
Dopamine agonist LED (mg) 256.3 264.3 240.0 0.0 400.0
Total medication LED (mg) 1376.5 604.5 1155.0 910.0 1515.0
Abbreviations: LED ¼ levodopa-equivalent dosage; SD ¼ standard deviation.
A. Juhasz et al. / Parkinsonism and Related Disorders xxx (2017) 1e84MoCA score showed any changes. Based on the MADRS, severity of
depression improved from 19 (IQR: 14e23) to 15 (IQR: 12e19)
points (p¼ 0.047, effect-size: 0.51), which can also be considered as
clinically meaningful by comparing to the respective MCID value.3.5. Side-effects
The observed LCIG therapy-related side-effects are summarized
in Table 3. Themajority of adverse events were either implantation-
or PEG-J-related and occurred within the ﬁrst 2 weeks after PEG-J
tube implantation. None of the enrolled patients discontinued the
treatment.4. Discussion
The aim of the present study was to measure the effects of LCIG
treatment on the patients' experiences of daily living. As far as the
authors are aware, this is the ﬁrst prospective multicenter study
utilizing the recent MDS-UPDRS and UDysRS scales to assess lon-
gitudinal changes in the disability caused by the non-motor and
motor symptoms of PD. Previous LCIG-related studies analyzed
only patient diaries and UPDRS-4 tomeasure changes in dyskinesia,
which could give mainly time- and severity-related data, but did
not provide information on the topical distribution of dyskinesia
and their impact on daily functioning [16,17]. Since the UDysRS has
distinct sections, we could independently analyze how the LCIG
treatment improved the severity and disability of dyskinesia and
their impact on the experiences of daily living [16].
A 1-year LCIG treatment considerably ameliorated both motor-
and non-motor symptoms of advanced PD. Based on the analysis of
MDS-UPDRS nM-EDL and M-EDL parts, we clearly demonstrated
that LCIG improved the impact of PD-related symptoms on the
experiences of daily living with large magnitude (effect-size).
Seemingly, it may be surprising that the MDS-UPDRS ME did not
change signiﬁcantly from baseline. Since both baseline and follow-
up MDS-UPDRS ME examinations were assessed in the ON state at
optimal pharmacological therapy, the patients had comparable
motor symptoms and consequently similar motor examinationPlease cite this article in press as: A. Juhasz, et al., Levodopa/carbidopa i
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As far as the authors are aware of, our paper is the ﬁrst to
evaluate the impact of LCIG on dyskinesia by the means of UDysRS
(PubMed search, keywords UDysRS and LCIG, UDysRS and Duo-
dopa, UDysRS and enteral levodopa, accessed on August 31, 2016).
The disability associated with dyskinesia (UDysRS-4) and the
impact of ON and OFF dyskinesia upon daily living (UDysRS-1 and
UDysRS-2, respectively) markedly ameliorated. Although the
objective severity of dyskinesia did not improve signiﬁcantly
(UDysRS-3), a p-value of 0.063 and an effect-size of 0.47 may
suggest a statistical under-power behind this phenomenon.
Meanwhile, the time spent with ON dyskinesia and OFF states
(MDS-UPDRS items 4.1 and 4.3) also signiﬁcantly decreased.
Consequently, the ‘good time’ signiﬁcantly and meaningfully
increased. Probably all of these prominent changes contributed to
the improvement in the HRQoL of our patients. Of note, the
magnitude of improvement in both PDQ-39 and EQ-5D was in the
range of the previously published studies [4,7].
Because many non-motor-symptoms are unrelated to dopa-
mine, it may be a surprising ﬁnding that the mood, cardiovascular
and sleep problems were also better controlled during LCIG treat-
ment. We can assume that the stable levodopa blood concentration
level and the OFF period reduction can yield improvement in
various non-motor symptoms by the reduction of non-motor
ﬂuctuations. While in some patients the severity of mood prob-
lems are completely unrelated to the motor performance, in other
subset of patients the severity of depression and/or anxiety worsen
to a great extent during OFF periods and becomesmild or negligible
during ON periods. In these cases LCIG can improvemood problems
by eliminating or reducing the OFF periods. Similarly, LCIG can also
improve orthostatic hypotension by eliminating high peak levo-
dopa blood concentration levels). Improvement in sleep quality
was also reported by other groups [30].
Similarly to a randomized trial on LCIG, most adverse events
(AEs) occurred within the ﬁrst two weeks after PEG-J tube im-
plantation [1]. Moreover, the majority of these early side-effects
were related to the surgical procedure (including pain or local in-
jection site complications) and mild to moderate in severityntestinal gel can improve both motor and non-motor experiences of
onism and Related Disorders (2017), http://dx.doi.org/10.1016/
Table 2
Comparison of clinical symptoms and their impact on experiences of daily living and health-related quality of life.
Baseline 1-year follow-up Statistics
Mean or
count
SD Median Percentile
25
Percentile
75
Mean or
count
SD Median Percentile
25
Percentile
75
p-
value
Effect
size
MDS-UPDRS MDS-UPDRS nM-EDL 19.7 6.9 20 14 23 16.7 6.9 16 12 20 0.044 0.51
MDS-UPDRS M-EDL 23.9 6.2 24 20 29 19.4 9.0 18 13 25 0.025 0.57
MDS-UPDRS ME 42.5 16.0 45 29 57 45.3 16.4 42 35 53 0.354 0.24
MDS-UPDRS MC 10.4 4.0 11 8 14 7.5 4.0 7 5 10 0.002 0.77
item 4.1 Dyskinesia time 2.8 1.1 3 1 3 2.1 1.2 2 1 2 0.045* 0.32
item 4.3 OFF time 1.9 0.9 2 1 3 1.2 0.8 1 1 2 0.002* 0.77
MDS-UPDRS Total score 96.4 20.6 98 84 111 89.2 27.5 83 68 108 0.049 0.46
UDysRS UDysRS Part1 ON dyskinesia 20.5 8.6 23 17 26 14.5 9.3 14 10 22 0.008 0.67
UDysRS Part2 OFF dyskinesia 9.5 4.7 11 6 14 6.3 4.2 6 4 9 0.008 0.67
UDysRS Part3 Impairment 9.9 5.2 10 8 12 6.9 5.2 8 0 12 0.063 0.47
UDysRS Part4 Disability 6.0 3.1 6 4 9 3.8 3.0 4 0 6 0.007 0.69
UDysRS Total Score 45.9 16.7 47 36 54 32.1 17.3 34 21 45 0.003 0.76
HRQoL Schwab-England Scale 60.0 17.3 60 50 80 67.4 17.3 70 60 80 0.524 0.16
EQ-5D index value 0.483 0.243 0.518 0.393 0.604 0.561 0.270 0.629 0.543 0.691 0.043 0.52
EQ-5D Visual Analogue Scale 51.0 18.4 50 40 60 60.8 14.4 60 50 70 0.011 0.64
PDQ-39 Mobility 55.7 27.5 56.3 33.8 77.5 45.0 25.6 40.0 25.0 67.5 0.027 0.56
PDQ-39 Activities of Daily Living 47.1 21.3 50.0 29.2 64.6 35.1 24.4 29.2 16.7 41.7 0.003 0.76
PDQ-39 Emotional well being 42.2 22.6 41.7 22.9 60.4 34.2 20.7 25.0 20.8 45.8 0.038 0.53
PDQ-39 Stigma 42.6 29.3 40.7 12.5 62.5 24.2 23.2 18.8 6.2 31.2 0.000 0.94
PDQ-39 Social support 14.8 15.4 8.3 8.3 25.0 10.6 12.4 8.3 0.0 16.7 0.434 0.20
PDQ-39 Cognition 30.1 18.4 25.0 18.8 43.8 23.1 13.9 18.8 12.5 37.5 0.054 0.49
PDQ-39 Communication 28.1 20.5 16.7 16.7 37.5 22.5 21.0 16.7 8.3 33.3 0.022 0.58
PDQ-39 Bodily discomfort 47.4 20.9 41.7 29.2 70.9 42.2 23.3 41.7 25.0 58.3 0.163 0.35
PDQ-39 Summary index 38.5 14.9 35.4 26.9 50.3 29.6 13.6 27.0 21.3 31.4 0.003 0.75
NMS Montgomery-Asberg Depression
Rating Scale
18.2 7.2 19 14 23 15.4 6.2 15 12 19 0.047 0.51
PDSS-2 27.2 10.5 25 19 34 23.2 12.0 20 14 29 0.042 0.34
Epworth Sleepiness Scale 9.1 4.8 8 6 14 8.1 4.6 7 4 11 0.225 0.31
Lille Apathy Rating Scale 19.0 10.0 19 29 13 20.4 7.4 22 26 14 0.807 0.06
NMSS Cardiovascular dysfunction
subscore
5.4 3.2 5 4 8 3.8 5.3 2 0 4 0.018 0.60
NMSS Sleep problems subscore 19.8 7.5 19 16 24 17.3 9.5 16 12 23 0.117 0.40
NMSS Mood problems subscore 24.4 17.4 24 10 34 18.3 11.6 16 12 26 0.029 0.56
NMSS Hallucinations subscore 3.3 5.7 1 0 3 2.1 3.7 0 0 2 0.453 0.19
NMSS Memory problems subscore 7.3 6.2 6 2 12 6.1 6.5 4 0 10 0.056 0.49
NMSS Gastrointestinal dysfunction
subscore
8.4 7.1 6 4 13 6.5 7.8 4 0 14 0.151 0.36
NMSS Urinary dysfunction
subscore
10.9 6.6 11 8 15 10.7 7.8 8 4 16 0.885 0.04
NMSS Sexual dysfunction subscore 2.8 4.8 0 0 4 1.5 4.8 0 0 0 0.092 0.43
NMSS Miscellaneous subscore 6.6 5.7 6 2 10 5.7 6.6 2 0 10 0.446 0.19
NMSS Total score 88.9 40.3 88 60 106 72.0 32.2 69 49 99 0.027 0.56
Patient diary ON time without dyskinesia
(hours)
4.9 2.8 4.0 3.5 6.0 10.0 4.6 10.8 8.3 13.8 0.011 0.65
ON time with slight dyskinesia
(Hours)
3.6 2.5 3.0 2.0 5.0 4.0 4.4 3.4 0.5 5.3 0.624 0.12
ON time with severe dyskinesia
(hours)
1.8 1.7 2.0 0.0 2.5 0.4 1.6 0.0 0.0 0.0 0.034 0.54
OFF time (hours) 6.3 3.6 5.0 4.0 9.0 1.0 1.3 0.5 0.0 1.8 0.001 0.87
Good time (hours) 8.5 3.2 8.0 6.0 10.5 14.0 2.8 14.8 13.0 15.5 0.001 0.87
Daytime Sleep Time (Hours) 0.7 1.1 0.0 0.0 1.0 0.9 1.0 1.0 0.0 1.5 0.147 0.37
Nighttime Sleep Time (Hours) 6.6 1.5 6.5 6.0 7.0 7.7 1.7 7.5 6.8 8.8 0.043 0.51
Neurocognitive Mini-Mental Status Examination 26.7 2.3 27 26 28 26.4 2.0 27 25 27 0.566 0.15
Montreal Cognitive Assessment 21.4 3.6 22 19 24 21.9 3.4 22 20 25 0.160 0.36
Uncorrected p-values are shown. Wilcoxon's test was applied with the exception of values marked with *, where Chi-square test was used.
Abbreviations: HRQoL¼Health-related Quality of Life; MC¼Motor Complications (Part IV of MDS-UPDRS); MDS-UPDRS¼ TheMovement Disorder Society-sponsored Uniﬁed
Parkinson's Disease Rating Scale; ME¼Motor Examination (Part III of MDS-UPDRS); M-EDL¼Motor Experiences of Daily Living (Part II of MDS-UPDRS); nM-EDL¼Non-motor
Experiences of Daily Living (Part I of MDS-UPDRS); NMSS¼ Non-motor Symptoms Scale; PD ¼ Parkinson's disease; PDSS-2 ¼ Parkinson's Disease Sleep Scale 2nd version;
SD ¼ standard deviation; UDysRS ¼ Uniﬁed Dyskinesia Rating Scale.
A. Juhasz et al. / Parkinsonism and Related Disorders xxx (2017) 1e8 5(Table 3). The overall number of patients having at least one AE was
approximately 88%, which is comparable to other studies having at
least 1-year follow-up (77% [2], 92% [3] and 47% [4]). Despite of this
high rate of AEs, the occurrence of severe AEs was much lower
(20.6%) similarly to other studies (23%e32%) [2e4]. Although
similar studies had a discontinuation rate of 4.2%e38.8% [1e4,8],
none of our patients were withdrawn from either the study or the
treatment due to AEs. In the ﬁrst year, 4 patients required PEJ tubePlease cite this article in press as: A. Juhasz, et al., Levodopa/carbidopa i
daily living in Parkinson’s disease: An open-label study, Parkins
j.parkreldis.2017.02.001replacement (Table 3). Despite regular B12 vitamin blood level
monitoring, we observed newly developed polyneuropathy in 2
patients (5.9%). Because we did not perform electroneurography,
we are unable to exclude the possibility of having subclinical
neuropathy at the time of LCIG treatment initiation. Although one
may think that LCIG can prevent impulse control disorders (ICD),
punding and dopamine dysregulation syndrome (DDS), we
observed one elderly male patient with the history of punding andntestinal gel can improve both motor and non-motor experiences of
onism and Related Disorders (2017), http://dx.doi.org/10.1016/
Table 3
Adverse effects associated with levodopa/carbidopa intestinal gel therapy.
AE category Preferred term Overall complications Early postoperative complications
(2weeks)
Late complications (>2weeks)
Number of patients Percentage Number of patients Percentage Number of patients Percentage
Patients with at least one AE 30 88.2% 28 82.4% 14 40.2%
Patients with at least one serious AE 7 20.6% 5 14.7% 6 17.6%
LCIG discontinuation 0 0.0% 0 0.0% 0 0.0%
Drug-related Weight decreased 5 14.7% 0 0.0% 5 14.7%
Hallucination/confusion 4 11.8% 1 2.9% 4 11.8%
Symptomatic orthostatic hypotension 3 8.8% 1 2.9% 3 8.8%
Polyneuropathy 2 5.9% 0 0.0% 2 5.9%
Impulse control disorder 1 2.9% 0 0.0% 1 2.9%
Dopamine dysregulation syndrome 1 2.9% 0 0.0% 1 2.9%
Surgery-related Abdominal pain 24 70.6% 24 70.6% 4 11.8%
Injection site infection (local) 5 14.7% 4 11.8% 1 2.9%
Postoperative wound infection 3 8.8% 3 8.8% 0 0.0%
Peritonitis 2 5.9% 2 5.9% 0 0.0%
Stoma-related Stoma infection (unrelated to surgery) 3 8.8% 0 0.0% 3 8.8%
Granuloma 8 23.5% 0 0.0% 8 23.5%
Buried bumper syndrome 0 0.0% 0 0.0% 0 0.0%
Device-related Intestinal tube occlusion 1 2.9% 0 0.0% 1 2.9%
Intestinal tube dislocation 3 8.8% 0 0.0% 3 8.8%
Intestinal tube kinking 1 2.9% 0 0.0% 1 2.9%
Intestinal tube replacements 4 11.8% 0 0.0% 4 11.8%
Intestinal perforation 0 0.0% 0 0.0% 0 0.0%
Pump breakage/malfunction 1 2.9% 0 0.0% 1 2.9%
Side-effects are categorized based on their temporal relation to PEG-J tube implantation either as early (within 2 weeks after implantation) or late (>2 weeks after im-
plantation). Since some patients experienced both early and late complications, the overall number of patients with complications does not necessarily equal with the sum of
patients with early and late complications.
Abbreviation: AE ¼ adverse event.
A. Juhasz et al. / Parkinsonism and Related Disorders xxx (2017) 1e86another young male with the history of DDS, whose behavioral
problems recurred on LCIG therapy and required psychiatric and
psychological treatment. In a recent Australian 1-year single center
study, Chang et al. described that four out of their 15 patients (27%)
developed ICD (pathological gambling or punding) or DDS despite
negative screening at treatment initiation. Two out of these four
patients had such prior known alterations before starting the pump
treatment, but in the cases of other two individuals these problems
developed newly [10].5. Conclusions
LCIG not only can decrease ﬂuctuations but can also improve the
motor and non-motor experiences of daily living. This improve-
ment can be consistently demonstrated by the UDysRS and the
MDS-UPDRS. Furthermore, several non-motor symptoms and the
HRQoL can also be ameliorated by LCIG therapy. Since our results
suggest the MDS-UPDRS and UDysRS can reliably detect the PD-
related changes following LCIG, we recommend that these recent
scales should be utilized in future LCIG studies.Financial disclosures
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